MOL Advance (膜尔新材) was founded with the support of the National Innovation Center for High-performance Medical Devices and Guangzhou Institute of Advanced Technology. It is a brand specializing in separation membrane materials and filters for biomedical and microelectronics fields.

The core team of MOL Advance, led by Dr. Chen Shunquan from the Guangzhou Institute of Advanced Technology (now the core team of MOL Advance), has engaged in research on various membrane materials for more than 10 years. They have led the completion of several National Key Research and Development Program projects and Guangdong Provincial Science and Technology Program projects, including the integrated research on quality evaluation-oriented green manufacturing technology and specialized equipment for traditional Chinese medicine with special membranes, as well as the development and filtration mechanism research of filter membranes for rapid virus capture, accumulating rich engineering experience.

From 2021 to 2022, under the support of the emergency research project "R&D and Industrialization of Ultrafiltration Membrane Modules for Vaccine Separation and Concentration Processes" by the Guangdong Provincial Department of Science and Technology, Dr. Chen's team delivered the first domestic ultrafiltration membrane sheet production line with 100% independent intellectual property rights, achieving stable mass production of series-specification ultrafiltration membrane sheets, which is of great significance for solving the "bottleneck problem" in vaccine production.

Over the years, the team has led and participated in the formulation of more than 22 national standards, industry standards, and group standards, with a total patent portfolio of over 100 items. The MOL Advance team masters key membrane-making processes and critical technologies for process scaling-up. It is one of the few domestic teams that simultaneously master non-solvent induced phase separation (NIPS), thermally induced phase separation (TIPS), and vapor-induced phase separation (VIPS), and has representative membrane products for these three methods in the biomedical and microelectronics fields.

In 2024, MOL Advanced Materials Technology (Shenzhen) Co., Ltd. completed its angel round financing with the support of investors including Guangzhou Gaojie, Nansha Financial Holdings, Guangzhou Financial Holdings, Qinzhi Capital, and Tianhao Pharmaceutical, and completed the construction of three major bases: Taishan, Taihang, and Kunlun in the same year. In early 2025, the Kunlun base obtained ISO9001 certification and 100,000-class cleanroom certification, with multiple products achieving large-scale mass production and being put into application in several biomedical enterprises.

MOL Advance has gradually achieved 100% self-developed and self-controlled capabilities in formula, process, equipment, packaging, and testing, with outstanding strength in customized membrane product development. Up to now, MOL Advance has developed a number of high-precision domestic biomedical filtration membranes and filters, such as ultrafiltration centrifuge tubes, ultrafiltration membrane modules, hollow fiber membrane columns, and disc filters. Meanwhile, it is actively promoting the R&D of new products for microelectronics, fillers, and other fields, including virus-removing filters, PMP degassing membranes, hydrofluoric acid-resistant filters, and membrane chromatography products.